Cargando…
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease
BACKGROUND: There is a need for biomarkers to support an accurate diagnosis of Parkinson’s disease (PD). Cerebrospinal fluid (CSF) has been a successful biofluid for finding neurodegenerative biomarkers, and modern highly sensitive multiplexing methods offer the possibility to perform discovery stud...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476347/ https://www.ncbi.nlm.nih.gov/pubmed/37667404 http://dx.doi.org/10.1186/s40035-023-00374-w |
_version_ | 1785100909895745536 |
---|---|
author | Paslawski, Wojciech Khosousi, Shervin Hertz, Ellen Markaki, Ioanna Boxer, Adam Svenningsson, Per |
author_facet | Paslawski, Wojciech Khosousi, Shervin Hertz, Ellen Markaki, Ioanna Boxer, Adam Svenningsson, Per |
author_sort | Paslawski, Wojciech |
collection | PubMed |
description | BACKGROUND: There is a need for biomarkers to support an accurate diagnosis of Parkinson’s disease (PD). Cerebrospinal fluid (CSF) has been a successful biofluid for finding neurodegenerative biomarkers, and modern highly sensitive multiplexing methods offer the possibility to perform discovery studies. Using a large-scale multiplex proximity extension assay (PEA) approach, we aimed to discover novel diagnostic protein biomarkers allowing accurate discrimination of PD from both controls and atypical Parkinsonian disorders (APD). METHODS: CSF from patients with PD, corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), multiple system atrophy and controls, were analysed with Olink PEA panels. Three cohorts were used in this study, comprising 192, 88 and 36 cases, respectively. All samples were run on the Cardiovascular II, Oncology II and Metabolism PEA panels. RESULTS: Our analysis revealed that 26 and 39 proteins were differentially expressed in the CSF of test and validation PD cohorts, respectively, compared to controls. Among them, 6 proteins were changed in both cohorts. Midkine (MK) was increased in PD with the strongest effect size and results were validated with ELISA. Another most increased protein in PD, DOPA decarboxylase (DDC), which catalyses the decarboxylation of DOPA (L-3,4-dihydroxyphenylalanine) to dopamine, was strongly correlated with dopaminergic treatment. Moreover, Kallikrein 10 was specifically changed in APD compared with both PD and controls, but unchanged between PD and controls. Wnt inhibitory factor 1 was consistently downregulated in CBS and PSP patients in two independent cohorts. CONCLUSIONS: Using the large-scale PEA approach, we have identified potential novel PD diagnostic biomarkers, most notably MK and DDC, in the CSF of PD patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00374-w. |
format | Online Article Text |
id | pubmed-10476347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104763472023-09-05 Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease Paslawski, Wojciech Khosousi, Shervin Hertz, Ellen Markaki, Ioanna Boxer, Adam Svenningsson, Per Transl Neurodegener Research BACKGROUND: There is a need for biomarkers to support an accurate diagnosis of Parkinson’s disease (PD). Cerebrospinal fluid (CSF) has been a successful biofluid for finding neurodegenerative biomarkers, and modern highly sensitive multiplexing methods offer the possibility to perform discovery studies. Using a large-scale multiplex proximity extension assay (PEA) approach, we aimed to discover novel diagnostic protein biomarkers allowing accurate discrimination of PD from both controls and atypical Parkinsonian disorders (APD). METHODS: CSF from patients with PD, corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), multiple system atrophy and controls, were analysed with Olink PEA panels. Three cohorts were used in this study, comprising 192, 88 and 36 cases, respectively. All samples were run on the Cardiovascular II, Oncology II and Metabolism PEA panels. RESULTS: Our analysis revealed that 26 and 39 proteins were differentially expressed in the CSF of test and validation PD cohorts, respectively, compared to controls. Among them, 6 proteins were changed in both cohorts. Midkine (MK) was increased in PD with the strongest effect size and results were validated with ELISA. Another most increased protein in PD, DOPA decarboxylase (DDC), which catalyses the decarboxylation of DOPA (L-3,4-dihydroxyphenylalanine) to dopamine, was strongly correlated with dopaminergic treatment. Moreover, Kallikrein 10 was specifically changed in APD compared with both PD and controls, but unchanged between PD and controls. Wnt inhibitory factor 1 was consistently downregulated in CBS and PSP patients in two independent cohorts. CONCLUSIONS: Using the large-scale PEA approach, we have identified potential novel PD diagnostic biomarkers, most notably MK and DDC, in the CSF of PD patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00374-w. BioMed Central 2023-09-04 /pmc/articles/PMC10476347/ /pubmed/37667404 http://dx.doi.org/10.1186/s40035-023-00374-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Paslawski, Wojciech Khosousi, Shervin Hertz, Ellen Markaki, Ioanna Boxer, Adam Svenningsson, Per Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease |
title | Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease |
title_full | Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease |
title_fullStr | Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease |
title_full_unstemmed | Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease |
title_short | Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease |
title_sort | large-scale proximity extension assay reveals csf midkine and dopa decarboxylase as supportive diagnostic biomarkers for parkinson’s disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476347/ https://www.ncbi.nlm.nih.gov/pubmed/37667404 http://dx.doi.org/10.1186/s40035-023-00374-w |
work_keys_str_mv | AT paslawskiwojciech largescaleproximityextensionassayrevealscsfmidkineanddopadecarboxylaseassupportivediagnosticbiomarkersforparkinsonsdisease AT khosousishervin largescaleproximityextensionassayrevealscsfmidkineanddopadecarboxylaseassupportivediagnosticbiomarkersforparkinsonsdisease AT hertzellen largescaleproximityextensionassayrevealscsfmidkineanddopadecarboxylaseassupportivediagnosticbiomarkersforparkinsonsdisease AT markakiioanna largescaleproximityextensionassayrevealscsfmidkineanddopadecarboxylaseassupportivediagnosticbiomarkersforparkinsonsdisease AT boxeradam largescaleproximityextensionassayrevealscsfmidkineanddopadecarboxylaseassupportivediagnosticbiomarkersforparkinsonsdisease AT svenningssonper largescaleproximityextensionassayrevealscsfmidkineanddopadecarboxylaseassupportivediagnosticbiomarkersforparkinsonsdisease |